Organizations Filed Purposes:
THE FOUNDATION RAISES MONEY TO FOSTER AND ADVANCE MEDICAL AND SCIENTIFIC RESEARCH TO FIND A CURE FOR DUCHENNE'S MUSCULAR DYSTROPHY. IN ADDITION, THE FOUNDATION SEEKS TO PREVENT AND ALLEVIATE SUFFERING & PROMOTE EDUCATION & AWARENESS OF DUCHENNE'S MUSCULAR DYSTROPHY.
The Foundation funds research activities to find a cure for Duchenne's Muscular Dystrophy (DMD). Currently there are a number of clinical trials underway for drugs developed to treat various aspects of DMD. In September 2016, Sarepta Therapeutics, won FDA approval for the use of its drug Exondys 51 for the treatment of DMD patients that have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping. In December 2019, Sarepta, won FDA approval for its new drug Vyondys 53 for the treatment of patients that have a confirmed mutation of the dystrophin gene connected to exon 53 skipping. Both treatments help approximately 21% of the patients afflicted with DMD.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Chanel Maddigan | DIRECTOR | 5 | $0 |
| Dennis Schrader | DIRECTOR | 5 | $0 |
| William Christ Esq | DIRECTOR | 5 | $0 |
| Benjamin B Roberts | DIRECTOR | 5 | $0 |
| George Hajduczok Esq | DIRECTOR | 5 | $0 |
| Robert Jellinick | DIRECTOR | 5 | $0 |
| Steve Szymanski | DIRECTOR | 5 | $0 |
| Richard Mazurchuk Phd | DIRECTOR | 5 | $0 |
| Gary Bichler | DIRECTOR | 5 | $0 |
| Raju Gulati Md | DIRECTOR | 5 | $0 |
| Peter Vito | DIRECTOR | 5 | $0 |
| Paul A Richardson Cpa | DIRECTOR | 5 | $0 |
| Anita Ballow | SECRETARY | 5 | $0 |
| David J Korzak | DIRECTOR | 5 | $0 |
| Thomas A Maher Cpa | TREASURER | 5 | $0 |
| Kenneth Manning Esq | VICE PRESIDENT | 5 | $0 |
| Neera Gulati Md | PRESIDENT | 10 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202031119349300618_public.xml